Clinical Efficacy of Quadruple Regimen Including Clarithromycin Sustained-Release Tablets for Primary Eradication of Helicobacter Pylori
10.13748/j.cnki.issn1007-7693.20230736
- VernacularTitle:含克拉霉素缓释片铋剂四联疗法初次根除幽门螺杆菌的临床疗效
- Author:
YANG Bo
1
;
LYU Lisong
1
;
XIN Chuanwei
1
Author Information
1. Tongde Hospital of Zhejiang Province, Hangzhou 310012, China
- Publication Type:Journal Article
- Keywords:
Helicobacter pylori;
clarithromycin;
sustained-release tablets;
primary eradication treatment
- From:
Chinese Journal of Modern Applied Pharmacy
2024;41(13):1813-1817
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE
To explore the clinical efficacy of clarithromycin sustained-release tablets in the primary eradication of Helicobacter pylori.
METHODS
Retrospective analysis of the data of patients with primary eradication of Helicobacter pylori admitted to the outpatient department of Tongde Hospital of Zhejiang Province from January 2019 to December 2020 was conducted. They were divided into three groups according to the choice of clarithromycin dosage form and dosage, namely, clarithromycin tablets 500 mg bid treatment group(group A), clarithromycin sustained-release tablets 500 mg bid treatment group(group B), and clarithromycin sustained-release tablets 500 mg qd treatment group(group C). At least 4 weeks after the end of treatment in each group, telephone follow-up was conducted to compare and analyze the efficacy, compliance, recurrence rate, incidence of adverse reactions, and cost effectiveness ratio of different treatment schemes for eradication.
RESULTS
After eliminating lost visits, a total of 350 cases were included in this study, including 132 cases in group A, 101 cases in group B, and 117 cases in group C. The overall eradication rates in each group were 95.45%, 92.08%, and 97.44%, respectively. Six patients with low compliance were excluded (3 in group A, 3 in group B, and 0 in group C), with eradication rates of 95.35%, 92.86%, and 97.44%, respectively. There was no significant difference in the eradication rate, compliance, recurrence rate, and incidence of adverse reactions among the groups, but the cost effectiveness ratio in group C was the lowest. Taking group A as a reference, the incremental cost effectiveness ratio for group C was ‒156.459.
CONCLUSION
Clarithromycin sustained-release tablets can be safely and effectively used in the primary eradication treatment of patients with Helicobacter pylori infection, and can be used according to the recommended dosage in the instructions.
